Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04662255
Title Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) (BRUIN-MCL-321)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Loxo Oncology, Inc.
Indications

mantle cell lymphoma

Therapies

Ibrutinib

Zanubrutinib

LOXO-305

Acalabrutinib

Age Groups: senior | adult
Covered Countries USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT


No variant requirements are available.